These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 10933719)

  • 1. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response.
    van Der Most RG; Murali-Krishna K; Ahmed R; Strauss JH
    J Virol; 2000 Sep; 74(17):8094-101. PubMed ID: 10933719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
    Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
    J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.
    Guirakhoo F; Arroyo J; Pugachev KV; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Soike K; Ratterree M; Monath TP
    J Virol; 2001 Aug; 75(16):7290-304. PubMed ID: 11462001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model.
    Chambers TJ; Liang Y; Droll DA; Schlesinger JJ; Davidson AD; Wright PJ; Jiang X
    J Virol; 2003 Mar; 77(6):3655-68. PubMed ID: 12610141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.
    Guirakhoo F; Pugachev K; Zhang Z; Myers G; Levenbook I; Draper K; Lang J; Ocran S; Mitchell F; Parsons M; Brown N; Brandler S; Fournier C; Barrere B; Rizvi F; Travassos A; Nichols R; Trent D; Monath T
    J Virol; 2004 May; 78(9):4761-75. PubMed ID: 15078958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses.
    Caufour PS; Motta MC; Yamamura AM; Vazquez S; Ferreira II; Jabor AV; Bonaldo MC; Freire MS; Galler R
    Virus Res; 2001 Nov; 79(1-2):1-14. PubMed ID: 11551641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
    Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
    Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction and biological properties of yellow fever 17D/dengue type 1 recombinant virus.
    Mateu GP; Marchevsky RS; Liprandi F; Bonaldo MC; Coutinho ES; Dieudonné M; Caride E; Jabor AV; Freire MS; Galler R
    Trans R Soc Trop Med Hyg; 2007 Mar; 101(3):289-98. PubMed ID: 17169387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
    Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
    Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus.
    Chang GJ; Hunt AR; Holmes DA; Springfield T; Chiueh TS; Roehrig JT; Gubler DJ
    Virology; 2003 Feb; 306(1):170-80. PubMed ID: 12620809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.
    Guirakhoo F; Zhang Z; Myers G; Johnson BW; Pugachev K; Nichols R; Brown N; Levenbook I; Draper K; Cyrek S; Lang J; Fournier C; Barrere B; Delagrave S; Monath TP
    J Virol; 2004 Sep; 78(18):9998-10008. PubMed ID: 15331733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue.
    Azevedo AS; Gonçalves AJ; Archer M; Freire MS; Galler R; Alves AM
    PLoS One; 2013; 8(3):e58357. PubMed ID: 23472186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects.
    Guy B; Nougarede N; Begue S; Sanchez V; Souag N; Carre M; Chambonneau L; Morrisson DN; Shaw D; Qiao M; Dumas R; Lang J; Forrat R
    Vaccine; 2008 Oct; 26(45):5712-21. PubMed ID: 18762226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.
    Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP
    Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells.
    Brandler S; Brown N; Ermak TH; Mitchell F; Parsons M; Zhang Z; Lang J; Monath TP; Guirakhoo F
    Am J Trop Med Hyg; 2005 Jan; 72(1):74-81. PubMed ID: 15728870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
    Pletnev AG; Bray M; Hanley KA; Speicher J; Elkins R
    J Virol; 2001 Sep; 75(17):8259-67. PubMed ID: 11483771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T Cell Responses Induced by DNA Vaccines Based on the DENV2 E and NS1 Proteins in Mice: Importance in Protection and Immunodominant Epitope Identification.
    Pinto PBA; Assis ML; Vallochi AL; Pacheco AR; Lima LM; Quaresma KRL; Pereira BAS; Costa SM; Alves AMB
    Front Immunol; 2019; 10():1522. PubMed ID: 31333657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
    Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
    Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.
    Monath TP; Levenbook I; Soike K; Zhang ZX; Ratterree M; Draper K; Barrett AD; Nichols R; Weltzin R; Arroyo J; Guirakhoo F
    J Virol; 2000 Feb; 74(4):1742-51. PubMed ID: 10644345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation and immunogenicity of recombinant yellow fever 17D-dengue type 2 virus for rhesus monkeys.
    Galler R; Marchevsky RS; Caride E; Almeida LF; Yamamura AM; Jabor AV; Motta MC; Bonaldo MC; Coutinho ES; Freire MS
    Braz J Med Biol Res; 2005 Dec; 38(12):1835-46. PubMed ID: 16302098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.